Business context and reporting period
The supplied filing is Ocuphire Pharma, Inc.’s unaudited Form 10-Q for the quarter and six months ended June 30, 2023; it does not identify Opus Genetics, Inc. Ocuphire is a clinical-stage ophthalmic biopharmaceutical company developing retinal and refractive-eye treatments. Its lead retinal candidate is APX3330; Nyxol is licensed to Viatris for specified indications and territories.
Financial performance and liquidity
| Metric | Q2 2023 | Six months 2023 | Comparable 2022 period |
|---|---|---|---|
| License and collaboration revenue | $3.7 million | $5.4 million | $0 |
| Operating expenses | $9.1 million | $16.9 million | Q2: $4.9 million; six months: $11.4 million |
| Operating loss | $5.4 million | $11.5 million | Q2: $4.9 million; six months: $11.4 million |
| Net loss | $5.0 million | $10.8 million | Q2: $4.9 million; six months: $11.5 million |
| Basic and diluted loss per share | $0.24 | $0.51 | Q2: $0.25; six months: $0.60 |
Q2 revenue was reimbursement for Nyxol development services, rather than product sales. Six-month operating cash use was $2.7 million, versus $10.0 million in 2022; cash and cash equivalents fell $2.7 million to $40.0 million. The filing attributes the lower cash use partly to operating asset and liability movements. There was no financing cash flow in the first half of 2023. At June 30, current assets were $43.5 million and current liabilities $5.8 million; total liabilities were $5.8 million, with no debt reported. Accumulated deficit was $82.2 million. The filing gives no conventional operating-margin measure; operating loss was $5.4 million on Q2 revenue of $3.7 million.
Material changes versus prior period
- Revenue began in 2023 as Nyxol collaboration reimbursements; the prior-year periods reported none.
- Six-month operating expenses rose $5.5 million, including higher Nyxol trial costs and G&A. G&A included $1.2 million of severance related to the former CEO’s departure and higher stock-based compensation.
- Six-month net loss narrowed by $0.8 million, principally reflecting revenue and higher other income, partly offset by expense growth.
- Cash used in operations decreased substantially year over year, while cash and cash equivalents were $40.0 million at period end, compared with $17.0 million at June 30, 2022.
Outlook, commentary and risks
- Management said cash on hand should fund planned expenditures and obligations for at least 12 months following August 11, 2023. The company may need additional capital thereafter; future funding may dilute shareholders or be unavailable on favorable terms.
- After quarter-end, Ocuphire entered an optional 30-month equity purchase agreement with Lincoln Park for up to $50 million. It issued 246,792 commitment shares; purchases are subject to conditions, including a $0.25 per-share price floor, so access to the full amount is not assured.
- APX3330’s Phase 2 ZETA-1 trial did not meet its primary endpoint, but met a prespecified secondary endpoint on preventing binocular diabetic-retinopathy worsening. An FDA End-of-Phase-2 meeting was confirmed for Q4 2023.
- Nyxol’s FDA action date for reversal of mydriasis was September 28, 2023; approval would trigger a $10 million milestone from Viatris. VEGA-2 presbyopia trial results were expected in Q4 2023. Remaining regulatory and sales milestones and royalties were constrained and no related revenue was recognized.
- Viatris reimburses budgeted Nyxol development costs, but product approval, milestone attainment and future royalty revenue remain uncertain. Management expects R&D expenses to increase as development advances.
- The former CEO’s employment ended April 19, 2023, and Richard Rodgers became interim CEO. Other disclosed risks include clinical and regulatory uncertainty, capital-market access, macroeconomic conditions and cash concentration: $39.5 million of cash equivalents was not FDIC-insured.
- No material legal proceedings were reported. Management said disclosure controls were effective as of June 30, 2023.
Important facts for investors to verify
- Confirm the issuer: the supplied filing is for Ocuphire Pharma, Inc., not Opus Genetics, Inc.
- Check subsequent outcomes for the Nyxol FDA decision and the expected VEGA-2 results, and any resulting milestone revenue.
- Assess APX3330’s next clinical and regulatory steps, particularly the FDA meeting and implications of missing ZETA-1’s primary endpoint.
- Review actual cash burn, the company’s stated runway assumptions, and whether Lincoln Park financing is used and on what dilution terms.
- Separate recurring collaboration reimbursements from uncertain milestones, royalties and future product revenue.